💬In plain words
What the trial is, and whether it could suit you
This study is evaluating the safety and effectiveness of Foquest (multilayer-release methylphenidate), a once-daily extended-release medication for attention-deficit/hyperactivity disorder (ADHD), in adults aged 65 years and older.
ADHD can persist into older age and is associated with reduced quality of life and difficulties with executive function. Foquest is currently approved in Canada for the treatment of ADHD in adults up to age 65, but there is very limited research on its use in older adults. People over 65 may respond differently to stimulant medications due to age-related changes in how the body processes drugs, other medical conditions, and increased sensitivity to cardiovascular side effects.
This is an open-label study, meaning all participants will know they are receiving the study medication. There is no placebo group. Participants will take Foquest once daily for approx
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
1. Male or female aged 65 years or older at the time of consent.
2. Mentally and physically competent to provide informed consent and willing to comply with the study protocol
3. Meets DSM-5 criteria for ADHD combined presentation, inattentive presentation, or hyperactive/impulsive presentation based on clinical history
4. SRS-5 score of 14 or greater at screening
5. AISRS total score of 24 or greater at baseline
6. Montreal Cognitive Assessment (MoCA) score of 26 or greater
Exclusion Criteria:
1. Satisfied with current ADHD treatment
2. History of myocardial infarction, arrhythmia, or congenital heart disease
3. Mean systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg measured in triplicate at screening despite treatment
4. Treated hypertension not stable on medication or with dose changes in the last 30 days
5. History of transient ischemic attack or stroke
6. Current or lifetime DSM-5 diagnosis of bipolar I or II disorder, cyclothymic disorder, or bipolar disorder not otherwise specified
7. Clinical history strongly suggestive of undiagnosed bipolar spectrum disorder
8. Active suicidal ideation or behavior per C-SSRS at screening
9. Current substance use disorder
10. History of drug or alcohol abuse in the last 10 years as defined by DSM-5 criteria for substance use disorder (moderate or severe)
11. True allergy to methylphenidate, history of serious adverse reactions to methylphenidate, or known non-response to methylphenidate
12. History of seizure disorder other than a single childhood febrile seizure before age 3
13. History of glaucoma, hyperthyroidism, thyrotoxicosis, advanced arteriosclerosis, or severe renal insufficiency (eGFR less than 30 mL/min/1.73 m²)
14. Use of a monoamine oxidase inhibitor currently or within the past 14 days
15. Abnormal baseline ECG including left ventricular hypertrophy or QTc greater than 450 ms (males) or greater than 470 ms (females)
16. History of heart failure, unexplained dyspnea on exertion, or newly identified murmur
17. MoCA score less than 26 or evidence of cognitive impairment
18. Currently considered a suicide risk in the opinion of the investigator
💊
What it tests
- Methylphenidate hydrochloride extended-release capsules
DAR Clinical Research Inc.
Ottawa, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky